Today UBS Reconfirms a Buy Rating on Sucampo Pharmaceuticals (NASDAQ:SCMP) and a $15 Target Price

October 13, 2017 - By Henry Gaston

 Today UBS Reconfirms a Buy Rating on Sucampo Pharmaceuticals (NASDAQ:SCMP) and a $15 Target Price

Investors sentiment decreased to 1.33 in 2017 Q2. Its down 0.06, from 1.39 in 2017Q1. It dropped, as 23 investors sold Sucampo Pharmaceuticals, Inc. shares while 40 reduced holdings. 25 funds opened positions while 59 raised stakes. 24.71 million shares or 3.79% less from 25.68 million shares in 2017Q1 were reported.

Nationwide Fund Advsr holds 13,608 shares. Invesco has invested 0% in Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP). Parametric Associate Lc, Washington-based fund reported 55,552 shares. Moreover, First Tru Advisors L P has 0% invested in Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) for 20,003 shares. Menta Cap Limited Liability Com holds 114,330 shares. Sabby Ltd Limited Liability Company owns 0.02% invested in Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) for 33,200 shares. Creative Planning has 0% invested in Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP). Eqis Mgmt Incorporated owns 31,639 shares. Legal And General Group Incorporated Public Limited Com owns 44,756 shares or 0% of their US portfolio. Stifel Fincl holds 0% in Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) or 12,225 shares. Stevens Cap Mngmt Lp has 0.02% invested in Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP). Tower Research Cap Llc (Trc) invested in 0% or 341 shares. Qs Investors Ltd reported 0.01% of its portfolio in Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP). Tudor Invest Corp Et Al holds 0.01% of its portfolio in Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) for 16,586 shares. 67,100 were accumulated by Adams Diversified Equity Fund Inc.

Sucampo Pharmaceuticals (NASDAQ:SCMP) Rating Reaffirmed

Recently, In an analyst note sent to investors and clients on 12 October, Sucampo Pharmaceuticals (NASDAQ:SCMP) shares have had their Buy Rating reiterated by research professionals at UBS, who currently has a $15 target price on company. This target by UBS suggests the possibile upside of 47.78 % from the last stock close.

Investors sentiment decreased to 1.33 in 2017 Q2. Its down 0.06, from 1.39 in 2017Q1. It dropped, as 23 investors sold Sucampo Pharmaceuticals, Inc. shares while 40 reduced holdings. 25 funds opened positions while 59 raised stakes. 24.71 million shares or 3.79% less from 25.68 million shares in 2017Q1 were reported.

Nationwide Fund Advsr holds 13,608 shares. Invesco has invested 0% in Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP). Parametric Associate Lc, Washington-based fund reported 55,552 shares. Moreover, First Tru Advisors L P has 0% invested in Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) for 20,003 shares. Menta Cap Limited Liability Com holds 114,330 shares. Sabby Ltd Limited Liability Company owns 0.02% invested in Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) for 33,200 shares. Creative Planning has 0% invested in Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP). Eqis Mgmt Incorporated owns 31,639 shares. Legal And General Group Incorporated Public Limited Com owns 44,756 shares or 0% of their US portfolio. Stifel Fincl holds 0% in Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) or 12,225 shares. Stevens Cap Mngmt Lp has 0.02% invested in Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP). Tower Research Cap Llc (Trc) invested in 0% or 341 shares. Qs Investors Ltd reported 0.01% of its portfolio in Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP). Tudor Invest Corp Et Al holds 0.01% of its portfolio in Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) for 16,586 shares. 67,100 were accumulated by Adams Diversified Equity Fund Inc.

Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) Ratings Coverage

Among 9 analysts covering Sucampo Pharma (NASDAQ:SCMP), 6 have Buy rating, 0 Sell and 3 Hold. Therefore 67% are positive. Sucampo Pharma has $31 highest and $11.0 lowest target. $21.33’s average target is 110.15% above currents $10.15 stock price. Sucampo Pharma had 31 analyst reports since August 6, 2015 according to SRatingsIntel. The firm earned “Buy” rating on Wednesday, August 2 by Maxim Group. The company was initiated on Monday, August 24 by H.C. Wainwright. The firm has “Hold” rating given on Wednesday, August 16 by Jefferies. The firm has “Buy” rating given on Wednesday, August 26 by Maxim Group. The firm earned “Buy” rating on Thursday, October 29 by Roth Capital. UBS initiated the stock with “Buy” rating in Tuesday, February 9 report. The stock of Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) earned “Buy” rating by Maxim Group on Tuesday, November 15. As per Friday, November 13, the company rating was maintained by Mizuho. WallachBeth Capital maintained it with “Hold” rating and $27 target in Thursday, August 27 report. The firm has “Neutral” rating by Mizuho given on Friday, October 9.

About 513,583 shares traded. Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) has declined 5.30% since October 13, 2016 and is downtrending. It has underperformed by 22.00% the S&P500.

Investors wait Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) to report on November, 8. its quarterly earnings Wall Street analysts expect $0.25 earnings per share, down $0.03 or 10.71 % from last year’s $0.28 same quarter earnings. This translates into $11.70 million profit for SCMP giving the stock a 10.15 P/E. This is assuming the current $0.25 EPS is accurate. Sucampo Pharmaceuticals, Inc.’s Wall Street analysts see -10.71 % negative EPS growth, taking into account the $0.28 EPS reproted in the previous quarter,

Sucampo Pharmaceuticals, Inc. is a biopharmaceutical company. The company has market cap of $474.84 million. The Firm is focused on the development and commercialization of pharmaceutical products. It currently has negative earnings. The Company’s primary focus areas are gastroenterology, ophthalmology and oncology-related disorders.

More recent Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) news were published by: Globenewswire.com which released: “Sucampo Pharmaceuticals Announces Webcast of Its Presentation at the 2017 …” on September 19, 2017. Also Bizjournals.com published the news titled: “Md. biotech expands HQ in ramp-up for potential drug approval” on September 19, 2017. Seekingalpha.com‘s news article titled: “Sucampo Firing Sales Torpedos” with publication date: September 07, 2017 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.